Questions: Vasculitis: Types and Pathological Mechanisms

Question 1

A 68-year-old woman presents with new temporal headache, jaw pain when chewing, and sudden painless vision loss in her right eye. ESR is markedly elevated. What is the most likely diagnosis, and what is the immediate clinical priority?

• A. IgA vasculitis — initiate immunosuppression to prevent renal involvement
• B. Giant cell arteritis with ophthalmic artery involvement — urgent treatment is required to prevent vision loss in the contralateral eye
• C. ANCA-associated vasculitis causing pulmonary-renal syndrome — check for hemoptysis
• D. Polyarteritis nodosa with mesenteric involvement — obtain angiography

Answer: (B)

The triad of temporal headache, jaw claudication, and sudden monocular vision loss in an older woman strongly suggests giant cell (temporal) arteritis — a large vessel vasculitis. Granulomatous inflammation of the temporal and ophthalmic arteries causes ischemia to the optic nerve. Once one eye is affected, the other is at immediate risk. This is treated as a medical emergency with high-dose corticosteroids even before biopsy confirmation, because the window to prevent bilateral blindness is narrow. Vessel size (large) determines the clinical syndrome: proximal cranial arteries, not small vessel or medium vessel beds.

Question 2

A 40-year-old man presents with simultaneous hemoptysis and hematuria. Kidney biopsy shows necrotizing glomerulonephritis with no immune complex deposits on immunofluorescence ('pauci-immune'). Serology is positive for anti-MPO antibodies. Which mechanism is responsible?

• A. IgG antibodies attacking glomerular basement membrane collagen IV, causing linear immunofluorescence
• B. ANCA binding to MPO on cytokine-primed neutrophil surfaces, activating neutrophils to attack the small vessel endothelium without immune complex deposition
• C. Immune complex deposition of IgA in glomerular and dermal capillary walls, activating complement
• D. Granulomatous Th1 inflammation destroying the aortic media, producing stenosis and aneurysm

Answer: (B)

ANCA-associated vasculitis is mechanistically distinctive: antibodies target intracellular enzymes (MPO or PR3) that are normally hidden inside neutrophil granules. When cytokines prime neutrophils during infection or systemic inflammation, these antigens transiently surface; ANCAs bind them, activating the neutrophil to attack the endothelium of small vessels. No immune complexes are deposited — hence 'pauci-immune' on biopsy. The pulmonary-renal syndrome (simultaneous hemoptysis and hematuria) results from the small vessel beds of both lungs and kidneys being targeted simultaneously.

Question 3

Most vasculitis is autoimmune in origin; infectious organisms do not directly cause blood vessel inflammation.

• T. True
• F. False

Answer: False

Infections can trigger vasculitis through two mechanisms: direct invasion of vessel walls by pathogens (as in bacterial endocarditis seeding small vessels), and immune complex formation when antigen-antibody complexes deposit in vessel walls (as seen in hepatitis B-associated polyarteritis nodosa and hepatitis C-associated cryoglobulinemic vasculitis). Recognizing infectious triggers matters therapeutically: treating the underlying infection is essential alongside immunosuppression, and standard immunosuppression alone may worsen infectious vasculitis.

Question 4

The clinical syndrome produced by vasculitis can be predicted with remarkable precision from the size of vessel affected: large vessel vasculitis causes proximal aortic stenosis or aneurysm; medium vessel vasculitis causes named muscular artery infarction; small vessel vasculitis causes glomerulonephritis, pulmonary hemorrhage, and palpable purpura.

• T. True
• F. False

Answer: True

Vessel size is the organizing principle of vasculitis classification precisely because it predicts organ involvement so reliably. Large vessels (aorta, major branches) develop granulomatous inflammation causing aneurysm or stenosis — hence arm claudication in Takayasu's, jaw claudication in GCA. Medium muscular arteries develop segmental necrotizing inflammation with microaneurysms — renal and mesenteric infarction in PAN, coronary aneurysms in Kawasaki. Small vessels (capillaries, arterioles, venules) supply the glomerulus, alveolus, and dermal capillary bed — hence the pulmonary-renal syndrome and palpable purpura signature of ANCA and IgA vasculitis.

Question 5

Explain why treating ANCA-associated vasculitis requires a different therapeutic approach than treating giant cell arteritis, despite both being forms of vasculitis.

Model answer: The two diseases have distinct immunological mechanisms. Giant cell arteritis is driven by granulomatous Th1 T-cell inflammation in the walls of large vessels, so high-dose corticosteroids that suppress T-cell-mediated immunity are the mainstay. ANCA-associated vasculitis is driven by ANCA antibodies (produced by B cells) activating neutrophils against small vessel endothelium. Treatment therefore targets both B cells (with rituximab, which depletes B cells producing the pathogenic antibodies) and neutrophil-endothelial interaction. While corticosteroids are used in both, the additional disease-specific agents differ because the upstream pathogenic mechanisms differ.

The shared label 'vasculitis' conceals mechanistically distinct diseases. Matching therapy to mechanism — rather than to the syndromic category — is what makes targeted treatment work. This is the therapeutic implication of the classification framework.